{"transactions":[{"id":1623695,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":93963,"kind":"person","name":"King Michael","position":1,"cik":"0001998530","reported_name":"King Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-23T21:45:19.000Z","date":"2024-02-21","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2014 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":115000,"derivative":{"exercise_price":5.17,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0000950170-24-019432","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024019432/ownership.xml","form_type":"4"}},{"id":1727277,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":93963,"kind":"person","name":"King Michael","position":1,"cik":"0001998530","reported_name":"King Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-11-30T22:00:07.000Z","date":"2023-11-30","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":0.9,"value":4500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 5,000 shares of the Issuer's common stock, par value $0.0001 per share, acquired by the reporting person in an open market transaction."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000950170-23-067072","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023067072/ownership.xml","form_type":"4"}},{"id":1750708,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":93963,"kind":"person","name":"King Michael","position":1,"cik":"0001998530","reported_name":"King Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-11-03T20:50:05.000Z","date":"2023-10-30","kind":"grant","planned":false,"acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents options to purchase shares of common stock of the Registrant pursuant to the Registrant's 2021 Omnibus Equity Incentive Plan. The exercise price of the options was determined as of the date that the compensation committee of the board of directors of the Registrant approved the award, October 19, 2023. The award was contingent upon the Reporting Person's commencement of service as Chief Financial Officer of the Registrant, which occurred on October 30, 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock of the Registrant pursuant to the Registrant's 2021 Omnibus Equity Incentive Plan. The exercise price of the options was determined as of the date that the compensation committee of the board of directors of the Registrant approved the award, October 19, 2023. The award was contingent upon the Reporting Person's commencement of service as Chief Financial Officer of the Registrant, which occurred on October 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, with 1/4 vesting on the one-year anniversary date from the Reporting Person's commencement of service as Chief Financial Officer (October 30, 2024), and the remainder vesting thereafter in equal monthly installments over a three year period."}],"balance_after":850000,"derivative":{"exercise_price":0.798,"expiration_date":"2033-10-30","underlying":"Common Stock","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0000950170-23-058894","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023058894/ownership.xml","form_type":"4"}}]}